Prescient (ASX:PTX) reports promising clinical data for PTX-100 in relapsed and refractory TCL – Kalkine Media
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of...
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has fielded more promising results from its PTX-100 T Cell...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced continuing positive results in the PTX-100 phase 1b...
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation...
Australia's clinical-stage oncology company Prescient Therapeutics (ASX: PTX) -- developing targeted therapies (PTX-100 and PTX-200)...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation...
Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for...
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.